Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND001 autologous cell therapy for COPD with impaired pulmonary diffusion function
CTR20220371Phase 2Completed
- Sponsor
- Jiangxi Xianhe Medical Technology
- Start
- Jun 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bronchial basal cells in chronic obstructive pulmonary disease (COPD), sponsored by Jiangxi Xianhe Medical Technology. Started Jun 2022; status: completed.
02
Drugs
autologous bronchial basal cells
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20220371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220371.